Reasons for not receiving standard of care treatment and effectiveness of capecitabine in stage III colon cancer patients in Alberta

  • Author / Creator
    El Shayeb, Mohamed
  • Adjuvant chemotherapy is the standard of care for stage-III colon cancer. Despite this, large proportions of patients do not receive it; the oncologist may not recommend it or the patient may refuse it. We aimed to identify the physicians’ and patients’ reasons for making treatment decisions. We also evaluated the effectiveness of newly-introduced capecitabine in real clinical practice. A retrospective population-based study was conducted that included all surgically-treated stage-III colon cancer patients in Alberta between 2002 and 2005 who had consultation with an oncologist. Chart reviews were conducted to extract treatment details, oncologists’ reasons for not recommending, and patients’ reasons for declining chemotherapy. A total of 613 patients met the inclusion criteria. Overall, 27% of the patients did not receive chemotherapy. The most frequent reason for not recommending chemotherapy was co-morbidity. Twenty-two percent of patients declined treatment due to toxicity concerns. Effectiveness results of capecitabine conformed to its efficacy.

  • Subjects / Keywords
  • Graduation date
  • Type of Item
  • Degree
    Master of Science
  • DOI
  • License
    This thesis is made available by the University of Alberta Libraries with permission of the copyright owner solely for non-commercial purposes. This thesis, or any portion thereof, may not otherwise be copied or reproduced without the written consent of the copyright owner, except to the extent permitted by Canadian copyright law.
  • Language
  • Institution
    University of Alberta
  • Degree level
  • Department
    • School of Public Health Sciences
  • Supervisor / co-supervisor and their department(s)
    • Macy Winget (Cancer Care, Alberta Health Services)
    • Yutaka Yasui (School of Public Health)
  • Examining committee members and their departments
    • Marcy Winget (Cancer Care, Alberta Health Services)
    • Andrew Scarfe (Faculty of Medicine and Dentistry, Cross Cancer Institute)
    • Yutaka Yasui ( School of Public Health)